4-(3,4-Dimethoxybenzoyl)-5-ethyl-1,3-dihydroimidazol-2-one | 83167-09-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3,4-Dimethoxybenzoyl)-5-ethyl-1,3-dihydroimidazol-2-one
• CAS: 83167-09-3
• 化学式: C₁₄H₁₆N₂O₄
• 分子量: 276.292
• InChiKey: BKQHOIRFAKZMTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-乙基-1,3-二氢-咪唑-2-酮 、 3,4-二甲氧基苯甲酰氯 在 三氯化铝 作用下， 以 硝基苯 为溶剂， 反应 6.0h， 以7%的产率得到4-(3,4-Dimethoxybenzoyl)-5-ethyl-1,3-dihydroimidazol-2-one
  参考文献：
  名称：

  4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents

  摘要：

  A series of 4-aroyl-1,3-dihydro-2H-imidazol-2-ones was synthesized and evaluated for pharmacological activity in the anesthetized dog. Most members of this series produced dose-related increases in cardiac contractile force as well as relatively minor increases in heart rate and decreases in systemic arterial blood pressure that were not blocked by propranolol. In general, 4-methoxy or 4-methylthiobenzoyl substitution afforded compounds of greatest inotropic potency. 1,3-Dihydro-4-(4-methoxybenzoyl)-5-methyl-2H-imidazol-one (6) was shown to produce a dose-related positive inotropic effect and reverse the depressant effect of pentobarbital on cardiac pump function in the dog heart-lung preparation. The cardiotonic activity of this series may have important utility in the treatment of congestive heart failure. 1,3-Dihydro-4-[4-(methylthio)benzoyl]-5-methyl-2H-imidazol-2-one (17) was chosen for human studies and is currently undergoing clinical trials.

  DOI：

  10.1021/jm00354a017

文献信息

• SCHNETTLER, R. A.;DAGE, R. C.;GRISAR, J. M., J. MED. CHEM., 1982, 25, N 12, 1477-1481
  作者：SCHNETTLER, R. A.、DAGE, R. C.、GRISAR, J. M.

  DOI：——

  日期：——
• 4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents
  作者：Richard A. Schnettler、Richard C. Dage、J. Martin Grisar

  DOI：10.1021/jm00354a017

  日期：1982.12

  A series of 4-aroyl-1,3-dihydro-2H-imidazol-2-ones was synthesized and evaluated for pharmacological activity in the anesthetized dog. Most members of this series produced dose-related increases in cardiac contractile force as well as relatively minor increases in heart rate and decreases in systemic arterial blood pressure that were not blocked by propranolol. In general, 4-methoxy or 4-methylthiobenzoyl substitution afforded compounds of greatest inotropic potency. 1,3-Dihydro-4-(4-methoxybenzoyl)-5-methyl-2H-imidazol-one (6) was shown to produce a dose-related positive inotropic effect and reverse the depressant effect of pentobarbital on cardiac pump function in the dog heart-lung preparation. The cardiotonic activity of this series may have important utility in the treatment of congestive heart failure. 1,3-Dihydro-4-[4-(methylthio)benzoyl]-5-methyl-2H-imidazol-2-one (17) was chosen for human studies and is currently undergoing clinical trials.